Clinical observation and efficacy predictors of the combined use of S1 and oxaliplatin in treating metastatic triple-negative breast cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005682

Enrollment

Unknown

Registered

2014-11-17

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic triple-negative breast cancer

Interventions

S-1 and Oxaliplatin:Oxaliplatin 130mg/m2 D1, S-1 50mg/m2, b.i.d. D1-14, repeated every 3 weeks

Control:Gemcitabine 1000mg/m2 Vinorelbine 25mg/m2 D1, D8, repeated every 3 weeks

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18-65 years old women; pathologically diagnosed as TNBC; having used taxane and anthracyclines in the secondary and (or) neoadjuvant therapy; recurrence or metastasis having been confirmed by imaging or pathology study; good general condition (physical score<20 and having lesions which can be evaluated or (and) observed (refer RECIST 1.1); indicators such as liver and kidney function, electrolytes meet the requirements of chemotherapy.

Exclusion criteria

Exclusion criteria: being unable to understand the test content and cooperate; refusing to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
The diameter of the measurable lesions;	—

Contacts

Public ContactNian Weiqi

nwqone@gmail.com+86 13368393500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026